Hospital
Keck Medical Center of Usc
Keck Medical Center of Usc was paid $36.70M by Medicaid between Jan 2021 and Nov 2024, across 168 billing codes. Its largest line is J9271, Injection, pembrolizumab, 1 mg — 16% of everything it billed.
33Billing provider infoKECK MEDICAL CENTER OF USC
LOS ANGELES, CA 90089
LOS ANGELES, CA 90089
33aNPI1417554528assigned 10/02/2020
33bProvider typeGeneral Acute Care Hospital
28Total paid$36.70M
24GClaims233,604
24DCodes billed168
24AFirst – last monthJan 2021 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#81 of 410
Median peer was paid$6.90M
This provider vs. median5.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 28,977 | $5.30M | |
| 2022 | 54,259 | $10.98M | |
| 2023 | 71,696 | $12.11M | |
| 2024incomplete | 78,672 | $8.31M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 16% | 1,139 | 939 | $5.85M |
| J9299 | Injection, nivolumab, 1 mg | 14% | 979 | 703 | $5.14M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 5.4% | 7,960 | 5,277 | $1.98M |
| J0897 | Injection, denosumab, 1 mg | 5.2% | 1,397 | 1,313 | $1.92M |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 5.1% | 394 | 289 | $1.89M |
| 96375 | Therapeutic injection; each additional sequential IV push | 4.0% | 5,578 | 3,204 | $1.48M |
| 80053 | Comprehensive metabolic panel | 3.7% | 20,442 | 14,706 | $1.37M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.8% | 1,188 | 1,180 | $1.04M |
| 99199 | Unlisted special service, procedure or report | 2.7% | 1,407 | 952 | $1.00M |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | 2.7% | 710 | 701 | $977K |
| 77386 | 2.6% | 734 | 66 | $970K | |
| 0250 | 2.4% | 4,383 | 2,604 | $884K |
156 more codes
| J9035 | Injection, bevacizumab, 10 mg | 2.4% | 435 | $872K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.3% | 16,851 | $856K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 2.1% | 2,085 | $774K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.9% | 21,947 | $690K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.4% | 2,168 | $508K |
| 74178 | 1.2% | 463 | $436K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 1.2% | 3,000 | $428K |
| J9022 | Injection, atezolizumab, 10 mg | 1.1% | 112 | $413K |
| J7050 | Infusion, normal saline solution, 250 cc | 1.0% | 7,393 | $382K |
| 96367 | <1% | 1,348 | $355K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,293 | $314K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,488 | $297K |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 3,732 | $275K |
| 77334 | <1% | 294 | $266K | |
| 83735 | <1% | 7,165 | $232K | |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 30 | $231K |
| 0510 | <1% | 6,154 | $216K | |
| 96415 | <1% | 1,757 | $204K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 614 | $182K |
| 0270 | <1% | 878 | $177K | |
| 0760 | <1% | 2,652 | $173K | |
| 96417 | <1% | 2,062 | $166K | |
| 77336 | <1% | 982 | $164K | |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | <1% | 197 | $163K |
| 96416 | <1% | 949 | $149K | |
| 77300 | <1% | 361 | $148K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 5,194 | $136K |
| 86900 | <1% | 2,613 | $132K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,233 | $131K |
| 84100 | <1% | 6,373 | $118K | |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | <1% | 23 | $115K |
| 80197 | <1% | 1,558 | $102K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 918 | $97K |
| 96411 | <1% | 986 | $94K | |
| 83615 | <1% | 4,747 | $83K | |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 626 | $81K |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 212 | $78K |
| 96401 | <1% | 757 | $73K | |
| Q3014 | Telehealth originating site facility fee | <1% | 3,688 | $73K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 71 | $72K |
| 86850 | <1% | 2,357 | $72K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 2,365 | $71K |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 647 | $69K |
| 87497 | <1% | 1,098 | $64K | |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | <1% | 111 | $61K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,520 | $60K |
| 77301 | <1% | 93 | $55K | |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | <1% | 165 | $55K |
| 96402 | <1% | 891 | $55K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,429 | $52K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 355 | $51K |
| 82378 | <1% | 2,919 | $50K | |
| 86901 | <1% | 2,610 | $47K | |
| 85610 | <1% | 2,064 | $46K | |
| 74174 | <1% | 54 | $42K | |
| 77066 | Tomosynthesis, mammo | <1% | 329 | $36K |
| Z7500 | <1% | 1,050 | $36K | |
| 81001 | <1% | 2,116 | $33K | |
| 83521 | <1% | 822 | $33K | |
| 36430 | <1% | 104 | $33K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 244 | $33K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 262 | $32K |
| 77338 | <1% | 112 | $31K | |
| 85730 | <1% | 1,288 | $28K | |
| 84153 | <1% | 1,644 | $27K | |
| 86301 | <1% | 1,600 | $26K | |
| 71250 | <1% | 132 | $26K | |
| 87799 | <1% | 676 | $25K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,212 | $24K |
| 82728 | <1% | 1,638 | $20K | |
| 84439 | <1% | 1,231 | $18K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 745 | $17K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 438 | $17K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 331 | $17K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 39 | $17K |
| 82105 | <1% | 738 | $17K | |
| 76642 | <1% | 127 | $16K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 283 | $16K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,028 | $15K |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 171 | $15K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 769 | $15K |
| 82784 | <1% | 479 | $14K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 729 | $13K |
| 84165 | <1% | 875 | $12K | |
| 86920 | <1% | 77 | $12K | |
| 84403 | <1% | 772 | $11K | |
| 83540 | <1% | 1,623 | $11K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 172 | $11K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,333 | $10K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 101 | $10K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 305 | $9K |
| 0272 | <1% | 401 | $8K | |
| 0710 | <1% | 47 | $8K | |
| 84550 | <1% | 652 | $8K | |
| 81479 | Unlisted molecular pathology procedure | <1% | 42 | $7K |
| 83550 | <1% | 1,609 | $7K | |
| 86803 | <1% | 360 | $7K | |
| 85027 | <1% | 598 | $6K | |
| 82565 | <1% | 160 | $6K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 103 | $6K |
| 88321 | <1% | 178 | $6K | |
| 84155 | <1% | 466 | $6K | |
| 80061 | Lipid panel | <1% | 1,074 | $6K |
| 87340 | <1% | 433 | $6K | |
| 86334 | <1% | 144 | $5K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 482 | $5K |
| A9270 | Non-covered item or service | <1% | 985 | $4K |
| 82607 | <1% | 437 | $4K | |
| 86704 | <1% | 255 | $4K | |
| Z7610 | <1% | 293 | $4K | |
| 88108 | <1% | 75 | $4K | |
| 87077 | <1% | 365 | $4K | |
| 0370 | <1% | 13 | $3K | |
| 99070 | <1% | 139 | $3K | |
| 87186 | <1% | 217 | $3K | |
| 82570 | <1% | 530 | $3K | |
| 85045 | <1% | 203 | $3K | |
| 77080 | <1% | 26 | $3K | |
| 86300 | <1% | 419 | $2K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 13 | $2K |
| 83880 | <1% | 149 | $2K | |
| 86140 | <1% | 270 | $2K | |
| 82746 | <1% | 295 | $1K | |
| 83970 | <1% | 53 | $1K | |
| 84156 | <1% | 292 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 50 | $1K |
| 86304 | <1% | 77 | $1K | |
| 83520 | <1% | 15 | $1K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 73 | $1K |
| J3490 | Unclassified drugs | <1% | 720 | $913.59 |
| 86141 | <1% | 234 | $911.40 | |
| 80076 | <1% | 182 | $859.92 | |
| 80047 | <1% | 148 | $784.29 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 45 | $613.53 |
| 52000 | <1% | 12 | $610.01 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 13 | $569.94 |
| 85652 | <1% | 349 | $546.15 | |
| 82043 | <1% | 219 | $484.77 | |
| 81003 | <1% | 119 | $484.66 | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 15 | $475.30 |
| 96377 | <1% | 48 | $454.91 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 123 | $452.91 |
| 85379 | <1% | 25 | $403.76 | |
| 86644 | <1% | 17 | $356.25 | |
| 82550 | <1% | 19 | $352.19 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 12 | $349.98 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 27 | $326.52 |
| 51798 | <1% | 13 | $247.85 | |
| 86317 | <1% | 89 | $244.10 | |
| 88142 | <1% | 26 | $231.87 | |
| 86769 | <1% | 15 | $203.48 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 32 | $137.68 |
| 82610 | <1% | 25 | $110.74 | |
| 82232 | <1% | 15 | $14.41 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 14 | $7.19 |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 62 | $3.08 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTAYLOR, JEANNINE (SECRETARY)
| Provider | Location | Paid |
|---|---|---|
| Keck Medical Center of Usc | Los Angeles, CA | $44.98M |
| Usc Verdugo Hills Hospital | Glendale, CA | $10.03M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.